Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (30788)	10/5/2000 1:26:23 PM
From: tuck	Respond to of 32384

bob, My mom owns 100 shares and is roughly at breakeven, on my pick of several years ago. I've traded LGND in the distant past, and continue to keep an eye on it. No position now. Am generally keeping my powder as dry as I can for at least a month. There are much better short targets than LGND, but it still has to prove it can get a selling product to market. LGND seems very good with the FDA, but their strategy is one with a long time horizon, and is taking even longer to unfold than management had hoped. Not much downside here, unless a major correction comes before December, which could easily happen. But significant upside is going to take a marketing coup by one of its lead compounds. I'll believe it when I see it, and if I see it I'll figure I can get on board before the mo players are done with it. Cheers, Tuck